Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn(University of California, Los Angeles), Philippe Merle(Hôpital de la Croix-Rousse), В. В. Бредер, Ann‐Lii Cheng(National Taiwan University), Yee Chao(National Cancer Center), Masatoshi Kudo(Kindai University), Stephen L. Chan(Chinese University of Hong Kong), Erluo Chen, Baek‐Yeol Ryoo(Asan Medical Center), Ho-Yeong Lim(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Bruno Daniele(Azienda Ospedaliera G.Rummo), Marcelo Garrido(Pontificia Universidad Católica de Chile), Jennifer J. Knox(National Cancer Center), Julien Edeline(Inserm), Mohamed Bouattour(Hôpital Beaujon), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Thomas Yau(University of Hong Kong), Sadahisa Ogasawara(Chiba University), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 210
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k